Cargando…
The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy
BACKGROUND: Salivary gland carcinomas (SGC) are extremely rare malignancies with only limited treatment options for the metastatic phase of the disease. Treatment with anti-CD47 antibodies could represent a potent therapy for SGCs by promoting the phagocytic clearance of tumor cells through various...
Autores principales: | Votava, Michal, Bartolini, Robin, Capkova, Linda, Smetanova, Jitka, Jiri, Vachtenheim, Kuchar, Martin, Kalfert, David, Plzak, Jan, Bartunkova, Jirina, Strizova, Zuzana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520840/ https://www.ncbi.nlm.nih.gov/pubmed/36171566 http://dx.doi.org/10.1186/s12885-022-10114-4 |
Ejemplares similares
-
Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response
por: Strizova, Zuzana, et al.
Publicado: (2021) -
The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor—Immune System Interplay
por: Kuchar, Martin, et al.
Publicado: (2021) -
Tumoral and paratumoral NK cells and CD8(+) T cells of esophageal carcinoma patients express high levels of CD47
por: Strizova, Zuzana, et al.
Publicado: (2020) -
Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
por: Ozaniak, Andrej, et al.
Publicado: (2021) -
The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials
por: Snajdauf, Martin, et al.
Publicado: (2021)